Search results
Nov 13, 2019 · Eva González-Barca, MD PhD 4 Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Barcelona, Spain Search for other works by this author on:
- Efficacy and Safety of Ibrutinib in Combination with ...
Conclusion: In indolent clinical forms of MCL frontline...
- Efficacy and Safety of Ibrutinib in Combination with ...
Eva González-Barca's 196 research works with 4,106 citations and 9,566 reads, including: Artificial intelligence classifies and predicts the outcome of primary CNS and nodal large B-cell...
Eva María González Fernández (born 5 November 1980) is a Spanish actress, tv host and beauty pageant titleholder who represented her country at the Miss Universe 2003 pageant.
Eva González Barca's 66 research works with 621 citations and 4,012 reads, including: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in...
Contributors: Eva Gonzalez Barca; Laura Tomás‐Roca; Anna Esteve; Marta Rodriguez; Lucía Gato; Ruth Alonso‐Alonso; Alejandro Martin Garcia‐Sancho; Raul Cordoba; Anna Monter‐Rovira; Mariana Bastos‐Oreiro et al.
Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide.
Nov 13, 2019 · Conclusion: In indolent clinical forms of MCL frontline ibrutinib in combination with rituximab has a high efficacy, including undetectable MRD in the majority of cases, with a predictable toxicity profile.
